发文分析
近年国家/地区发文量统计
| 国家/地区 | 数量 |
|---|---|
| USA | 39 |
| CHINA MAINLAND | 38 |
| Iran | 4 |
| Italy | 4 |
| Canada | 3 |
| France | 3 |
| Norway | 3 |
| Denmark | 2 |
| England | 2 |
| GERMANY (FED REP GER) | 2 |
近年机构发文量统计
| 机构 | 数量 |
|---|---|
| ZHENGZHOU UNIVERSITY | 16 |
| HUAZHONG UNIVERSITY OF SCIENCE & TECHNOLOGY | 11 |
| LOMA LINDA UNIVERSITY | 5 |
| UNIVERSITY OF CALIFORNIA SYSTEM | 5 |
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC... | 3 |
| NEW YORK MEDICAL COLLEGE | 3 |
| ZHEJIANG UNIVERSITY | 3 |
| AARHUS UNIVERSITY | 2 |
| ARAK UNIV MED SCI | 2 |
| BRISTOL-MYERS SQUIBB | 2 |
近年文章引用他刊数据
| 文章名称 | 引用次数 |
|---|---|
| Mechanisms for estrogen receptor expression in human can... | 26 |
| The role of neoantigen in immune checkpoint blockade the... | 24 |
| Emerging therapies in advanced hepatocellular carcinoma | 16 |
| Organoid technology in disease modelling, drug developme... | 15 |
| Advances and perspectives of PARP inhibitors | 13 |
| Achievements and futures of immune checkpoint inhibitors... | 13 |
| Personalized prescription of tyrosine kinase inhibitors ... | 12 |
| Recent advances on blinatumomab for acute lymphoblastic ... | 11 |
| An integrated view of the role of miR-130b/301b miRNA cl... | 9 |
| Venetoclax with azacitidine targets refractory MDS but s... | 9 |
近年被他刊引用数据
| 期刊名称 | 引用次数 |
|---|---|
| J HEMATOL ONCOL | 27 |
| CANCERS | 14 |
| EXP HEMATOL ONCOL | 14 |
| BRIT J HAEMATOL | 12 |
| BIOMARK RES | 10 |
| SCI REP-UK | 9 |
| FRONT IMMUNOL | 8 |
| J CELL PHYSIOL | 8 |
| PLOS ONE | 8 |
| FRONT ONCOL | 7 |